Imatinib Mesylate Treatment in Two Patients with Idiopathic Hypereosinophilic Syndrome

作者
Sonja Payne,Michael J. Kovacs
出处
期刊:Annals of Pharmacotherapy [SAGE Publishing]
卷期号:38 (7-8): 1215-1218 被引量:4
标识
DOI:10.1345/aph.1d505
摘要

OBJECTIVE: To report 2 clinical cases of hypereosinophilic syndrome (HES) refractory to standard therapy and the variable responses to imatinib mesylate, and to review previously reported cases of imatinib mesylate use in the treatment of hypereosinophilia. case summaries: Two male patients were diagnosed with idiopathic HES complicated with organ involvement. Both were treated with imatinib mesylate after failing to respond to or being unable to tolerate standard therapy. In one patient, treatment with imatinib mesylate 100 mg/day produced resolution of symptoms and peripheral blood cell counts within 6 days. The patient has successfully maintained normal blood cell counts and has been without symptoms for more than one year after starting imatinib mesylate. The other patient failed to respond to imatinib mesylate even at the maximum dose (up to 400 mg/day). DISCUSSION: Imatinib mesylate was considered an appropriate alternative for standard therapy of HES based on the evidence that other treatments used for chronic myelogenous leukemia have also been successful in treating HES. Three small studies have supported this hypothesis. However, not all patients with HES respond to imatinib mesylate therapy. The cases presented here illustrate the marked difference. CONCLUSIONS: Imatinib mesylate has shown some promise in the treatment of HES. However, until the etiology of idiopathic hypereosinophilia and the role of imatinib mesylate in the resolution of this disease are determined, it will continue to be difficult to predict the responsiveness of a patient to imatinib mesylate therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Akim的应助被steplight采纳,获得10
刚刚
情怀的应助被steplight采纳,获得10
刚刚
李健的应助被steplight采纳,获得10
刚刚
rongliy发布了新的文献求助10
刚刚
打打的应助被steplight采纳,获得10
刚刚
斯文败类的应助被steplight采纳,获得10
1秒前
爆米花的应助被steplight采纳,获得10
1秒前
大个的应助被steplight采纳,获得10
1秒前
1秒前
Ava的应助被steplight采纳,获得10
1秒前
科目三的应助被steplight采纳,获得10
1秒前
在水一方的应助被steplight采纳,获得10
1秒前
糊糊完成签到,获得积分10
1秒前
2秒前
2秒前
2秒前
flying发布了新的文献求助60
4秒前
sleep完成签到,获得积分10
4秒前
5秒前
洋洋芋发布了新的文献求助10
6秒前
可一可再完成签到 ,获得积分10
7秒前
方方土完成签到,获得积分20
7秒前
科研通AI65的应助被DW采纳,获得10
7秒前
Hello的应助被steplight采纳,获得10
8秒前
隐形曼青的应助被steplight采纳,获得10
8秒前
OK的应助被steplight采纳,获得50
8秒前
无花果的应助被steplight采纳,获得10
8秒前
所所的应助被steplight采纳,获得10
8秒前
思源的应助被steplight采纳,获得10
8秒前
科目三的应助被steplight采纳,获得10
8秒前
田様的应助被steplight采纳,获得10
8秒前
Nole的应助被steplight采纳,获得10
8秒前
秋风的应助被steplight采纳,获得10
8秒前
8秒前
skyleon完成签到,获得积分10
8秒前
8秒前
云淡风轻发布了新的文献求助10
9秒前
9秒前
闪闪的向珊完成签到 ,获得积分10
9秒前
Owen的应助被细心鲂采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188353
求助须知:如何正确求助?哪些是违规求助? 9576169
关于积分的说明 21845860
捐赠科研通 7786410
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482235